Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Malignant Melanoma

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 34 articles:
HTML format

Single Articles

    April 2024
  1. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    PubMed     Abstract available

  2. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    PubMed     Abstract available

    February 2024
  3. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    Retraction notice to "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model" [Cancer Lett. 419 (2018) 30-39].
    Cancer Lett. 2024 Feb 2:216670. doi: 10.1016/j.canlet.2024.216670.
    PubMed     Abstract available

    January 2024
  4. ZHANG J, Joshua AM, Yue L, O'Meara CH, et al
    Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
    Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633.
    PubMed     Abstract available

  5. LIU C, Cheng X, Han K, Hong L, et al
    A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
    Cancer Lett. 2024 Jan 19:216663. doi: 10.1016/j.canlet.2024.216663.
    PubMed     Abstract available

    November 2023
  6. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    PubMed     Abstract available

  7. HU X, Hu Z, Zhang H, Zhang N, et al
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Cancer Lett. 2023 Nov 7:216466. doi: 10.1016/j.canlet.2023.216466.
    PubMed     Abstract available

    September 2023
  8. XU M, Li S
    Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
    Cancer Lett. 2023 Sep 18:216397. doi: 10.1016/j.canlet.2023.216397.
    PubMed     Abstract available

    July 2023
  9. ZHANG X, Hu Z, Wang X, Li L, et al
    Corrigendum to "ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation" [Cancer Lett. 519 (2021) 237-249].
    Cancer Lett. 2023 Jul 18:216310. doi: 10.1016/j.canlet.2023.216310.

    April 2023
  10. ZHAN D, Zheng N, Zhao B, Cheng F, et al
    Expanding individualized therapeutic options via genoproteomics.
    Cancer Lett. 2023;560:216123.
    PubMed     Abstract available

    March 2023
  11. ZHAO J, Gao N, Xu J, Zhu X, et al
    Novel strategies in melanoma treatment using silver nanoparticles.
    Cancer Lett. 2023 Mar 27:216148. doi: 10.1016/j.canlet.2023.216148.
    PubMed     Abstract available

    December 2022
  12. DENG S, Banerjee S, Chen H, Pochampally S, et al
    SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Cancer Lett. 2022 Dec 31:216046. doi: 10.1016/j.canlet.2022.216046.
    PubMed     Abstract available

    October 2022
  13. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
    Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
    Cancer Lett. 2022;546:215850.
    PubMed     Abstract available

    August 2022
  14. LIU Y, Wang X, Zhu W, Sui Z, et al
    TRPML1-induced autophagy inhibition triggers mitochondrial mediated apoptosis.
    Cancer Lett. 2022;541:215752.
    PubMed     Abstract available

    July 2022
  15. DU Z, Feng Y, Zhang H, Liu J, et al
    Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation.
    Cancer Lett. 2022 Jul 31:215841. doi: 10.1016/j.canlet.2022.215841.
    PubMed     Abstract available

  16. TYAGI A, Wu SY, Watabe K
    Metabolism in the progression and metastasis of brain tumors.
    Cancer Lett. 2022;539:215713.
    PubMed     Abstract available

    May 2022
  17. LAURIN KM, Coutu-Beaudry K, Salazar A, Meribout N, et al
    Low expression of PGC-1beta and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1.
    Cancer Lett. 2022 May 17:215738. doi: 10.1016/j.canlet.2022.215738.
    PubMed     Abstract available

    October 2021
  18. TIAN C, Liu J, Zhou H, Li J, et al
    Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Cancer Lett. 2021;518:49-58.
    PubMed     Abstract available

    September 2021
  19. BHATTARAI PY, Kim G, Poudel M, Lim SC, et al
    METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation.
    Cancer Lett. 2021;522:44-56.
    PubMed     Abstract available

    July 2021
  20. ZHANG X, Hu Z, Wang X, Li L, et al
    ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
    Cancer Lett. 2021 Jul 26. pii: S0304-3835(21)00360.
    PubMed     Abstract available

    June 2021
  21. SINGHAL SS, Srivastava S, Mirzapoiazova T, Horne D, et al
    Targeting the mercapturic acid pathway for the treatment of melanoma.
    Cancer Lett. 2021;518:10-22.
    PubMed     Abstract available

    April 2021
  22. COPPO R, Orso F, Virga F, Dalmasso A, et al
    ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.
    Cancer Lett. 2021;510:13-23.
    PubMed     Abstract available

    March 2021
  23. GRILLO E, Corsini M, Ravelli C, Zammataro L, et al
    Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
    Cancer Lett. 2021;507:80-88.
    PubMed     Abstract available

  24. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available

    February 2021
  25. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available

  26. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available

    January 2021
  27. WU PK, Hong SK, Park JI
    Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf(V600E) melanoma cells.
    Cancer Lett. 2021 Jan 10. pii: S0304-3835(21)00007.
    PubMed     Abstract available

  28. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available

  29. ZHAO Y, Li J, Ting KK, Chen J, et al
    The VE-Cadherin/beta-catenin signalling axis regulates immune cell infiltration into tumours.
    Cancer Lett. 2021;496:1-15.
    PubMed     Abstract available

    December 2020
  30. BOTELHO DE SOUZA LE, Ferreira FU, Thome CH, Brand H, et al
    Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome.
    Cancer Lett. 2020 Dec 28. pii: S0304-3835(20)30701.
    PubMed     Abstract available

    November 2020
  31. HARTMAN ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, et al
    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30635.
    PubMed     Abstract available

  32. KIM G, Bhattarai PY, Lim SC, Kim JY, et al
    PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
    Cancer Lett. 2020 Nov 27. pii: S0304-3835(20)30631.
    PubMed     Abstract available

    April 2020
  33. TIAN H, Kang Y, Song X, Xu Y, et al
    PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Cancer Lett. 2020;476:170-182.
    PubMed     Abstract available

  34. KUO CL, Chou HY, Chiu YC, Cheng AN, et al
    Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis.
    Cancer Lett. 2020;474:138-150.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.